|
Virtual Meetings 2021
Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with HER2-Positive Breast CancerFor more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153. PARTICIPATING FACULTY
Adam M Brufsky, MD, PhD Professor of Medicine Co-Director, Comprehensive Breast Cancer Center UPMC Hillman Cancer Center Associate Division Chief, Division of Hematology/Oncology Department of Medicine University of Pittsburgh Pittsburgh, Pennsylvania Karen A Gelmon, MD Professor of Medicine University of British Columbia Medical Oncologist, BC Cancer Vancouver, British Columbia, Canada Erika Hamilton, MD Director, Breast and Gynecologic Research Program Sarah Cannon Research Institute/Tennessee Oncology Nashville, Tennessee Sara Hurvitz, MD Professor of Medicine David Geffen School of Medicine at UCLA Director, Breast Cancer Clinical Research Program Co-Director, Santa Monica-UCLA Outpatient Oncology Practice Santa Monica, California Reshma Mahtani, DO Associate Professor of Medicine Co-Leader, Breast Cancer Program Sylvester Cancer Center University of Miami Miami, Florida Hope S Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California, San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco, California Sara M Tolaney, MD, MPH Chief, Division of Breast Oncology Associate Director, Susan F Smith Center for Women's Cancers Senior Physician Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Tiffany A Traina, MD Vice Chair, Oncology Care Section Head, Triple-Negative Breast Cancer Clinical Research Program Associate Attending Physician Breast Medicine Service Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor Weill Cornell Medical College New York, New York SERIES MODERATOR Neil Love, MD Research To Practice Agenda
MODULE 1: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer MODULE 2: Optimizing the Management of HER2-Positive Metastatic Breast Cancer MODULE 3: Treatment of HER2-Positive Brain Metastases MODULE 4: Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy
Target Audience
CME Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Brufsky — Consulting Agreements: Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Myriad Genetic Laboratories Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Spectrum Pharmaceuticals Inc. Dr Gelmon — Advisory Committee: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Lilly, Merck, Mylan, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals; Expert Testimony: Genentech, a member of the Roche Group. Dr Hamilton — Advisory Committee and Consulting Agreements (to Institution): Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Lilly, Merck, Mersana Therapeutics, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Silverback Therapeutics; Contracted Research (to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana-Farber Cancer Hospital, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, InventisBio, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics, Merus BV, Molecular Templates, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Orinove Inc, Pfizer Inc, PharmaMar, Plexxikon Inc, Polyphor, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Torque Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks. Dr Hurvitz — Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Dignitana AB, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed LLC, Sanofi Genzyme, Seagen Inc, Zymeworks; Stock Investment: NKMax; Stock Investment (Spouse): Ideal Implant Incorporated, ROMTech. Dr Mahtani — Consulting Agreements: Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Eisai Inc, Immunomedics Inc, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi Genzyme, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: University of Miami. Dr Rugo — Consulting Agreement: Samsung Bioepis (limited consulting); Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Honoraria: Mylan, Puma Biotechnology Inc; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc. Dr Tolaney — Consulting Agreements: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Athenex, BeyondSpring Inc, Bristol-Myers Squibb Company, Certara, Chugai Pharmaceutical Co Ltd, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, Kyowa Kirin Co Ltd, Lilly, Merck, Mersana Therapeutics, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc. Dr Traina — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, Athenex Inc, Ayala Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Exact Sciences Inc, Foundation Medicine, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Ionis Pharmaceuticals Inc, iTeos Therapeutics, Merck, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Carrick Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Innocrin Pharmaceuticals Inc, Novartis, Pfizer Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Seagen Inc. |